Swiss TPH has extensive expertise in clinical trial service provision, with a successful track record of operating and facilitating research in resource-constraint settings for over 20 years. We understand the barriers to conducting clinical trials in difficult settings and offer strategic, customised solutions with a high level of flexibility. We appreciate the intricacies of strategic planning in these settings and aim to deliver the highest quality data for clinical trials tailored to each unique project.
We do this through:
- Local know-how of regional context
- Understanding the patient pathway in various settings
- Academic and scientific innovation
- Clinical expertise and management
- Global network of partners and collaborators
We propose study designs and monitoring solutions to promote evidence-based practices that lead to meaningful, sustainable and effective outputs. By working with healthcare providers in an open, transparent manner, we enrich our local understanding and thus enhance the quality to deliver customer-focused clinical trials.
Access to effective, evidence-based medicine is a fundamental right, not a privilege.
Promoting evidence-based medicine and conducting clinical research requires customised and optimised solutions with a fully integrated, robust quality system at each level – starting at the earliest development stages through to final implementation. Provision of the highest quality and data integrity will allow the downstream use of collected data for the evaluation of drugs, diagnostics and vaccines, ultimately enabling FDA or EMA accreditation of successful candidates, support evidence-based medicine practices and contribute to national and international disease management guidelines. Our dedicated team is committed to these principles.
We are a global, experienced, multidisciplinary, multilingual team comprised of scientists, clinicians, and experienced medical and administrative staff. Through our combined clinical, research and local expertise with long-standing partnerships in an extensive global network of regional collaborators, we aim to deliver the highest-quality consumer-focused clinical trial results.
The ANTICOV study aims to identify one or two treatments that could be used to treat mild and moderate cases of COVID-19, to stop the disease from getting more serious. The goal of the study is to find a treatment to help avoid mass hospitalizations in African health systems with limited intensive care facilities. If successful, it will also have important implications for other regions. Read more about ANTICOV
Human Africa Trypanosomiasis is a life-threatening neglected disease. To date nifurtimox-eflornithine combined therapy (NECT) is the Standard Treatment for late-stage HAT. Nevertheless, NECT is still far from ideal given the environment in which HAT patients live. There is an urgent need to develop less toxic and easier-to-use products. One promising agent is Fexinidazole. Read more about the project
Schistosomes, parasitic blood flukes, cause the chronic disaese schistosomiasis. Today, the gold standard of treatment is praziquantel which is only suitable for adults and school-aged children. Thus, a palliative, effective and safe praziquantel formulation to treat young children is absolutely required. To reach this aim, the Pediatric Praziquantel Consortium was founded in 2012. More information
Tuberculosis is one of the most deadly infectious diseases in the world. Treatment is complex especially in case of multidrug-resistant tuberculosis. Particularly patients in low-resource countries often lack access or do not complete treatment regimen. TB PRACTECAL is a pioneering new clinical trial aiming to find a radically improved course of treatment for drug-resistant tuberculosis. Read more about the project
Our Study Sites
Selected ProjectsAll Projects
Latest PublicationsAll Publications
Kümmerle A et al. Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: report from a field study. PLoS Negl Trop Dis. 2021;15(11):e0009903. DOI: 10.1371/journal.pntd.0009903
Mahende M.K et al. Comparative palatability of orally disintegrating tablets (ODTs) of praziquantel (L-PZQ and Rac-PZQ) versus current PZQ tablet in African children: a randomized, single-blind, crossover study. PLoS Negl Trop Dis. 2021;15(6):e0007370. DOI: 10.1371/journal.pntd.0007370
Mesu V.K.B.K et al. Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study. Lancet Glob Health. 2021;9(7):e999-e1008. DOI: 10.1016/s2214-109x(21)00208-4
N'Goran E et al. Challenges and lessons from conducting a paediatric clinical trial in sub-Saharan Africa: the case of the praziquantel oral dispersible tablets phase II study in Côte d'Ivoire. Adv Parasitol. 2019;103:75-89. DOI: 10.1016/bs.apar.2018.09.002
Steiner-Monard V et al. The candidate blood-stage malaria vaccine P27A induces a robust humoral response in a fast track to the field phase I trial in exposed and non exposed volunteers. Clin Infect Dis. 2019;68(3):466-474. DOI: 10.1093/cid/ciy514